168 related articles for article (PubMed ID: 34711160)
1. Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer.
Shaikh J; Patel K; Khan T
Mini Rev Med Chem; 2022; 22(8):1197-1215. PubMed ID: 34711160
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
[TBL] [Abstract][Full Text] [Related]
3. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
4. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
El-Naggar AM; El-Hashash MA; Elkaeed EB
Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
6. Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor.
Opoku-Temeng C; Dayal N; Hernandez DE; Naganna N; Sintim HO
Chem Commun (Camb); 2018 May; 54(36):4521-4524. PubMed ID: 29629444
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
[TBL] [Abstract][Full Text] [Related]
8. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
Rana S; Sonawane YA; Taylor MA; Kizhake S; Zahid M; Natarajan A
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3736-3740. PubMed ID: 30343954
[TBL] [Abstract][Full Text] [Related]
10. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
[TBL] [Abstract][Full Text] [Related]
12. Discovery of
Fanta BS; Lenjisa J; Teo T; Kou L; Mekonnen L; Yang Y; Basnet SKC; Hassankhani R; Sykes MJ; Yu M; Wang S
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049714
[TBL] [Abstract][Full Text] [Related]
13. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design.
Rath SL; Senapati S
PLoS One; 2013; 8(9):e73836. PubMed ID: 24058495
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
17. Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2.
Hummel JR; Xiao KJ; Yang JC; Epling LB; Mukai K; Ye Q; Xu M; Qian D; Huo L; Weber M; Roman V; Lo Y; Drake K; Stump K; Covington M; Kapilashrami K; Zhang G; Ye M; Diamond S; Yeleswaram S; Macarron R; Deller MC; Wee S; Kim S; Wang X; Wu L; Yao W
J Med Chem; 2024 Feb; 67(4):3112-3126. PubMed ID: 38325398
[TBL] [Abstract][Full Text] [Related]
18. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]